Viani Karina, Furlong William, Filho Vicente Odone, Santos Murra Mariana Dos, Nabarrete Juliana Moura, Ladas Elena, Barr Ronald Duncan
Instituto de Tratamento do Câncer Infantil (ITACI), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo. São Paulo, Brazil.
Centre for Health Economics and Policy Analysis, McMaster University, Hamilton, Canada.
Hematol Transfus Cell Ther. 2024 Dec;46 Suppl 6(Suppl 6):S228-S233. doi: 10.1016/j.htct.2024.05.014. Epub 2024 Sep 7.
Neuroblastomas account for 8-10 % of all cancer diagnoses among children. Most patients present with advanced, high-risk disease and 90 % are less than five years old. The burden of morbidity and mortality is high and is quantifiable by measures of health-related quality of life (HRQL). Measuring quality of life in under five-year-old children is a particular challenge that has been met with the development of the Health Utilities Pre-School (HuPS) instrument. Quality of life studies in children with cancer are scarce in low- and middle-income countries and are usually conducted at a single center, thus limiting any conclusions drawn. This pilot study aimed to assess the health-related quality of life of children at the time of diagnosis of high-risk neuroblastomas.
This prospective cross-sectional multicentric study assessed the quality of life of children with high-risk neuroblastoma. The Health Utilities Pre-School instrument was applied to under five-year-olds, and the related Health Utilities Index Mark 3 instrument to over five-year olds.
Eleven patients participated in this study. There was a high burden of morbidity at diagnosis, often equating to severe disability, indicative of states of health with scores worse than being dead in two under five-year-old children.
The results of the current study will help to set research priorities for subsequent investigations and provide a basis to improve supportive care for children with high-risk neuroblastoma.
神经母细胞瘤占儿童所有癌症诊断病例的8 - 10%。大多数患者就诊时患有晚期高危疾病,90%的患者年龄小于5岁。发病和死亡负担很高,可通过健康相关生活质量(HRQL)指标进行量化。测量5岁以下儿童的生活质量是一项特殊挑战,而健康效用学前量表(HuPS)工具的开发解决了这一问题。在低收入和中等收入国家,针对癌症儿童的生活质量研究很少,且通常在单一中心进行,因此限制了所得出的任何结论。这项试点研究旨在评估高危神经母细胞瘤患儿诊断时的健康相关生活质量。
这项前瞻性横断面多中心研究评估了高危神经母细胞瘤患儿的生活质量。健康效用学前量表应用于5岁以下儿童,相关的健康效用指数第3版量表应用于5岁以上儿童。
11名患者参与了本研究。诊断时发病负担很高,常等同于严重残疾,这表明两名5岁以下儿童的健康状况得分比死亡还要差。
本研究结果将有助于确定后续调查的研究重点,并为改善高危神经母细胞瘤患儿的支持性护理提供依据。